We proudly share with you a J. Med. Chem. article about highly selective type-II kinase inhibitors. For this article Mercachem scientists were involved in the design and synthesis of these inhibitors, the project being a spin-off from our internal innovation projects.
"We are honored to have had the opportunity to collaborate with the groups of Prof. Dr. Stefan Knapp and Prof. Dr. Stefan Laufer, two experts in the area of kinase inhibitors," comments Dr. Koen Hekking. "By recognizing the trimodular nature of the original DNA-encoded library hit, and applying an iterative, semi-parallel approach to the different building blocks, our group managed to synthesize a diverse set of compounds. This eventually led to the identification of a highly selective inhibitor for the inactive states of p38α/β."
Mercachem continues investing in expertise and quality within several innovation projects,which are open for partnering.
Röhm, Sandra et al., J. Med. Chem, 2019 (62), 10757-10782, "Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors"